Is Inhibikase Therapeutics Stock a Good Investment?
Inhibikase Therapeutics Investment Advice | IKT |
- Examine Inhibikase Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Inhibikase Therapeutics' leadership team and their track record. Good management can help Inhibikase Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Inhibikase Therapeutics' business and its evolving consumer preferences.
- Compare Inhibikase Therapeutics' performance and market position to its competitors. Analyze how Inhibikase Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Inhibikase Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Inhibikase Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Inhibikase Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Inhibikase Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Good | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Inhibikase Therapeutics Stock
Researching Inhibikase Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 3.12. Inhibikase Therapeutics had not issued any dividends in recent years. The entity had 1:6 split on the 30th of June 2023.
To determine if Inhibikase Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Inhibikase Therapeutics' research are outlined below:
| Inhibikase Therapeutics is way too risky over 90 days horizon | |
| Inhibikase Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 260.5 K. Reported Net Loss for the year was (19.03 M) with loss before taxes, overhead, and interest of (8.26 M). | |
| Inhibikase Therapeutics has about 32.21 M in cash with (18.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.28. | |
| Latest headline from news.google.com: Inhibikase Potential To Improve Current Treatment Options For PAH Patients - Seeking Alpha |
Inhibikase Therapeutics Quarterly Accounts Payable |
|
Inhibikase Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Inhibikase Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Inhibikase Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Inhibikase Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Inhibikase Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-15 | 2023-03-31 | -0.14 | -0.16 | -0.02 | 14 | ||
2022-03-31 | 2021-12-31 | -0.17 | -0.2 | -0.03 | 17 | ||
2021-11-15 | 2021-09-30 | -0.14 | -0.18 | -0.04 | 28 | ||
2021-08-16 | 2021-06-30 | -0.38 | -0.22 | 0.16 | 42 | ||
2023-08-14 | 2023-06-30 | -0.92 | -1.11 | -0.19 | 20 | ||
2024-03-27 | 2023-12-31 | -0.85 | -0.64 | 0.21 | 24 | ||
2023-11-14 | 2023-09-30 | -1.12 | -0.86 | 0.26 | 23 | ||
2024-11-12 | 2024-09-30 | -0.37 | -0.65 | -0.28 | 75 |
Know Inhibikase Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Inhibikase Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Inhibikase Therapeutics backward and forwards among themselves. Inhibikase Therapeutics' institutional investor refers to the entity that pools money to purchase Inhibikase Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | Redmond Asset Management, Llc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 626.5 K | Blair William & Co | 2024-06-30 | 116.1 K | Geode Capital Management, Llc | 2024-09-30 | 50.1 K | Renaissance Technologies Corp | 2024-09-30 | 19.9 K | Vanguard Group Inc | 2024-09-30 | 16.7 K | State Street Corp | 2024-06-30 | 10.1 K |
Inhibikase Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 183.44 M.Market Cap |
|
Inhibikase Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.31) | (1.38) | |
| Return On Capital Employed | (1.82) | (1.72) | |
| Return On Assets | (1.31) | (1.38) | |
| Return On Equity | (1.73) | (1.65) |
Determining Inhibikase Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Inhibikase Therapeutics is a good buy. For example, gross profit margin measures Inhibikase Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Inhibikase Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Inhibikase Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Inhibikase Therapeutics. Check Inhibikase Therapeutics' Beneish M Score to see the likelihood of Inhibikase Therapeutics' management manipulating its earnings.
Evaluate Inhibikase Therapeutics' management efficiency
Inhibikase Therapeutics has Return on Asset of (0.7621) % which means that on every $100 spent on assets, it lost $0.7621. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.4969) %, meaning that it generated no profit with money invested by stockholders. Inhibikase Therapeutics' management efficiency ratios could be used to measure how well Inhibikase Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.38 in 2024. Return On Capital Employed is likely to gain to -1.72 in 2024. At this time, Inhibikase Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 18.3 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 85.6 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.06 | 2.05 | |
| Tangible Book Value Per Share | 2.06 | 2.05 | |
| Enterprise Value Over EBITDA | 0.09 | 0.09 | |
| Price Book Value Ratio | 0.62 | 0.65 | |
| Enterprise Value Multiple | 0.09 | 0.09 | |
| Price Fair Value | 0.62 | 0.65 | |
| Enterprise Value | -2 M | -1.9 M |
Understanding the management dynamics of Inhibikase Therapeutics allows us to gauge its ability to sustain growth and profitability. This comprehensive analysis aids in determining the stock's value.
Beta 1.118 |
Basic technical analysis of Inhibikase Stock
As of the 29th of November, Inhibikase Therapeutics retains the Risk Adjusted Performance of 0.1497, downside deviation of 5.61, and Market Risk Adjusted Performance of 0.7433. Inhibikase Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Inhibikase Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inhibikase Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inhibikase Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Inhibikase Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Inhibikase Therapeutics' Outstanding Corporate Bonds
Inhibikase Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Inhibikase Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Inhibikase bonds can be classified according to their maturity, which is the date when Inhibikase Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| INGREDION INC 32 Corp BondUS457187AB87 | View | |
| US457187AC60 Corp BondUS457187AC60 | View | |
| US457187AD44 Corp BondUS457187AD44 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand Inhibikase Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Inhibikase Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1497 | |||
| Market Risk Adjusted Performance | 0.7433 | |||
| Mean Deviation | 4.73 | |||
| Semi Deviation | 4.76 | |||
| Downside Deviation | 5.61 | |||
| Coefficient Of Variation | 544.15 | |||
| Standard Deviation | 6.71 | |||
| Variance | 44.99 | |||
| Information Ratio | 0.1651 | |||
| Jensen Alpha | 1.03 | |||
| Total Risk Alpha | 0.2127 | |||
| Sortino Ratio | 0.1974 | |||
| Treynor Ratio | 0.7333 | |||
| Maximum Drawdown | 37.4 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 14.93 | |||
| Downside Variance | 31.46 | |||
| Semi Variance | 22.65 | |||
| Expected Short fall | (5.60) | |||
| Skewness | 0.5176 | |||
| Kurtosis | 1.28 |
| Risk Adjusted Performance | 0.1497 | |||
| Market Risk Adjusted Performance | 0.7433 | |||
| Mean Deviation | 4.73 | |||
| Semi Deviation | 4.76 | |||
| Downside Deviation | 5.61 | |||
| Coefficient Of Variation | 544.15 | |||
| Standard Deviation | 6.71 | |||
| Variance | 44.99 | |||
| Information Ratio | 0.1651 | |||
| Jensen Alpha | 1.03 | |||
| Total Risk Alpha | 0.2127 | |||
| Sortino Ratio | 0.1974 | |||
| Treynor Ratio | 0.7333 | |||
| Maximum Drawdown | 37.4 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 14.93 | |||
| Downside Variance | 31.46 | |||
| Semi Variance | 22.65 | |||
| Expected Short fall | (5.60) | |||
| Skewness | 0.5176 | |||
| Kurtosis | 1.28 |
Consider Inhibikase Therapeutics' intraday indicators
Inhibikase Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Inhibikase Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Inhibikase Therapeutics Corporate Filings
| 18th of November 2024 Other Reports | ViewVerify | |
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 8th of November 2024 Other Reports | ViewVerify | |
13A | 28th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Inhibikase Stock media impact
Far too much social signal, news, headlines, and media speculation about Inhibikase Therapeutics that are available to investors today. That information is available publicly through Inhibikase media outlets and privately through word of mouth or via Inhibikase internal channels. However, regardless of the origin, that massive amount of Inhibikase data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Inhibikase Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Inhibikase Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Inhibikase Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Inhibikase Therapeutics alpha.
Inhibikase Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Inhibikase Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Inhibikase Therapeutics Corporate Management
| Roger Rush | Head Research | Profile | |
| BSc FRCPC | Interim Advisor | Profile | |
| Garth LeesRolfe | Chief Officer | Profile | |
| Joseph CPA | Chief Officer | Profile | |
| Surendra Singh | Manufacturing Chemistry | Profile | |
| Dan Williams | Controller | Profile |
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.